ea0026s15.3 | Emerging therapies in type 2 diabetes | ECE2011
Sorensen Torekov Signe
Incretin-based therapies, such as the injectable GLP-1 receptor agonists and orally administered DPP-4 inhibitors, have recently been introduced into clinical practice. At present, the GLP-1 receptor agonists need to be administered once or twice daily. Several once weekly GLP-1 receptor agonists are in phase 3 development. This review examines the efficacy, safety and perspective for the future of the once weekly GLP-1 receptor agonists: exenatide once weekly, taspoglutide, a...